Fig. 1From: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyTime to response, duration of response, and time on therapy (weeks) in arm N + S. Patients with confirmed response are presented (n = 18)Back to article page